Priming Immunity at the beginning of Life - Perinatal
Networks
-
Variables
-
Efficacy of Bifidobacterium longum subsp. infantis, Bifidobacterium animalis subsp. lactis (BB-12), and Lactobacillus acidophilus (La-5) probiotics early in life of preterm infants to prevent colonization with multidrug-resistant organisms or highly epidemic bacteria (MDRO+) and to shape the microbiome of preterm infants toward the eubiotic state of healthy full-term infants.
Associated study
- Germany
| Acronym | PRIMAL |
|---|---|
| Name | Priming Immunity at the beginning of Life |
| Study design | Clinical trial |
| Number of very preterm (VPT) and/or very low birthweight (VLBW) births included in cohort (live & still births) | 475 |
| Number of term-born control births included in cohort (live & still births) | 0 |
| Countries |
|
Population
PRIMAL
Inclusion of moderate preterm infants born at 28+0 to 32+6 weeks of gestational age
Data Collection Event
Perinatal
Primary study with data collection from prenatal maternal data and data concerning the preterm infant from birth to discharge, with FU planned at 6 months, 1 year and 2 years of corrected age.